EFFICIENCY OF THE USING THE PREPARATION URSOSAN FORTE BY SICK PEOPLEWITH METABOLIC SYNDROME

Аннотация

Introduction: Metabolic syndrome is a cluster of factors associated with an increased risk of atherosclerotic cardiovascular diseases and diabetes mellitus [4-17]. Currently, immune inflammation is considered one of the main factors in the development of cardiovascular pathology. An increase in inflammatory indicators such as interleukins (IL) -1 and 6, and tumor necrosis factor-α (TNF-α) is associated with a high risk of complications in cardiac pathology and is considered an immunological marker of cardiovascular risk [2]. The aim of our study was to investigate the levels of interleukins 6 and 17 in patients with metabolic syndrome before and after treatment with Ursosan forte. Materials and methods: We examined the clinical and immunological parameters of 40 individuals, including 18 women and 22 men aged 25 to 55 years with a body mass index of 25.0 - 32.2 kg/m2, and 30 people in the control group of generally healthy individuals. Results: The conducted studies have established that in metabolic syndrome, activation of the cytokine system is observed, which is manifested by a multiple-fold increase in the serum levels of IL-6 and IL-17. It should be noted that in patients with metabolic syndrome both with and without hypertension, the levels of the studied cytokines were practically identical. The administered therapy had a positive effect on the cytokine status. In patients with a BMI greater than 30 kg/m2, the levels of IL-6 and IL-17 significantly exceeded the cytokine content in patients with a BMI up to 30 kg/m2. The therapy led to a decrease in IL-6 levels but did not significantly affect IL-17 levels.